Seegene Inc operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Seegene Inc with three other
pharmaceutical manufacturers in Asia:
Getein Biotech Inc
sales of 488.58 million Chinese Renmimbi [US$77.60 million]
Guangdong Hybribio Biotech Co Ltd
(479.09 million Chinese Renmimbi [US$76.09 million]
Green Cross Medical Science Corp
(98.39 billion Korean Won [US$91.70 million]
of which 100%
Seegene Inc reported sales of 87.66 billion Korean Won (US$81.70 million)
December of 2017.
increase of 19.0%
versus 2016, when the company's sales were 73.69 billion Korean Won.
Sales at Seegene Inc have increased during each of the previous five years
(and since 2012, sales have increased a total of 70%).